Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
A6ND01
UPID:
JUNO_HUMAN
Alternative names:
Folate receptor 4; Folate receptor delta; IZUMO1 receptor protein JUNO
Alternative UPACC:
A6ND01
Background:
Sperm-egg fusion protein Juno, also known as Folate receptor 4, Folate receptor delta, and IZUMO1 receptor protein JUNO, plays a pivotal role in fertilization. It serves as the receptor for IZUMO1, present on the oocyte surface, facilitating species-specific gamete recognition essential for successful fertilization. This interaction, while crucial for sperm-egg adhesion, does not directly induce cell fusion.
Therapeutic significance:
Understanding the role of Sperm-egg fusion protein Juno could open doors to potential therapeutic strategies.